John M. Hatcher, Ph.D.

Affiliations: 
2011 Chemistry Duke University, Durham, NC 
 2012- Cancer Biology Dana-Farber Cancer Institute/Harvard Medical School 
Google:
"John Hatcher"
Mean distance: 8.46
 
SNBCP

Parents

Sign in to add mentor
Don M. Coltart grad student 2011 Duke
 (An Umpolung Approach to the alpha-Functionalization of Ketones and Aldehydes.)
Nathanael Gray post-doc 2012-2015 Harvard Medical School/Dana-Farber Cancer Institute
Nathanael Gray research scientist 2015- Harvard Medical School/Dana-Farber Cancer Institute
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hatcher JM, Zwirek M, Sarhan AR, et al. (2023) Development of a Highly Potent and Selective Degrader of LRRK2. Bioorganic & Medicinal Chemistry Letters. 129449
Gao Y, Jiang B, Kim H, et al. (2023) Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. Journal of Medicinal Chemistry
Chow HY, Karchugina S, Groendyke BJ, et al. (2022) Development and Utility of a PAK1-Selective Degrader. Journal of Medicinal Chemistry. 65: 15627-15641
Malone CF, Kim M, Alexe G, et al. (2022) Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors. Cancer Research
Powell CE, Hatcher JM, Jiang J, et al. (2022) Selective Macrocyclic Inhibitors of DYRK1A/B. Acs Medicinal Chemistry Letters. 13: 577-585
Son J, Jang J, Beyett TS, et al. (2022) A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer. Cancer Research
Hatcher JM, Vatsan PS, Wang E, et al. (2021) Development of Highly Potent and Selective Pyrazolopyridine Inhibitor of CDK8/19. Acs Medicinal Chemistry Letters. 12: 1689-1693
Donovan KA, Ferguson FM, Bushman JW, et al. (2020) Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell
Hatcher JM, Yang G, Wang L, et al. (2020) Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. Acs Medicinal Chemistry Letters. 11: 2238-2243
Gray NS, Teng M, Jiang J, et al. (2020) Development of CDK2 and CDK5 Dual Degrader TMX-2172. Angewandte Chemie (International Ed. in English)
See more...